BMRN Stock - BioMarin Pharmaceutical Inc.
Unlock GoAI Insights for BMRN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B |
| Gross Profit | $2.27B | $1.89B | $1.59B | $1.38B | $1.34B |
| Gross Margin | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% |
| Operating Income | $484.21M | $185.77M | $160.97M | $-82,341,000 | $-43,440,000 |
| Net Income | $426.86M | $167.65M | $141.56M | $-64,080,000 | $854.03M |
| Net Margin | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% |
| EPS | $2.25 | $0.89 | $0.76 | $-0.35 | $4.75 |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Leerink Partners | Downgrade | Market Perform | $60 |
| November 6th 2025 | Stifel | Downgrade | Hold | $61 |
| September 8th 2025 | H.C. Wainwright | Initiation | Neutral | $60 |
| September 3rd 2025 | Raymond James | Initiation | Outperform | $85 |
| July 3rd 2025 | Morgan Stanley | Resumed | Overweight | $97 |
| February 24th 2025 | Oppenheimer | Upgrade | Outperform | $98 |
| November 15th 2024 | Wolfe Research | Initiation | Outperform | $95 |
| October 30th 2024 | William Blair | Downgrade | Market Perform | - |
| October 10th 2024 | Raymond James | Resumed | Outperform | $79 |
| August 20th 2024 | Bernstein | Upgrade | Outperform | $110← $94 |
| May 17th 2024 | Robert W. Baird | Downgrade | Neutral | $72← $104 |
| May 14th 2024 | Evercore ISI | Initiation | Outperform | $113 |
| November 15th 2023 | Wells Fargo | Initiation | Overweight | $100 |
| October 23rd 2023 | Bernstein | Upgrade | Market Perform | $82 |
| September 28th 2023 | Raymond James | Initiation | Market Perform | - |
Earnings History & Surprises
BMRNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | $0.94 | — | — | — |
Q4 2025 | Oct 27, 2025 | $-0.15 | $0.12 | +180.0% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $0.86 | $1.44 | +67.2% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $0.94 | $1.13 | +20.2% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $0.54 | $0.92 | +70.4% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $0.78 | $0.91 | +16.7% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $0.36 | $0.96 | +168.3% | ✓ BEAT |
Q2 2024 | Apr 24, 2024 | $0.31 | $0.71 | +127.7% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $0.44 | $0.49 | +11.4% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.46 | $0.46 | 0.0% | = MET |
Q3 2023 | Jul 31, 2023 | $0.47 | $0.54 | +14.9% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.43 | $0.60 | +39.5% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.07 | $0.36 | +614.3% | ✓ BEAT |
Q4 2022 | Oct 26, 2022 | $0.37 | $0.45 | +21.6% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.43 | $0.59 | +37.2% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $0.38 | $0.55 | +44.7% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $0.03 | $0.03 | +0.4% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $0.11 | $0.18 | +63.6% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.30 | $0.53 | +76.7% | ✓ BEAT |
Latest News
Key deals this week: Trump Media & Technology, Howard Hughes, BioMarin Pharmaceutical and more
➖ NeutralBioMarin Pharmaceutical shares are trading higher after the company announced an agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total equity value of ~$4.8 billion.
📈 PositiveAmicus Therapeutics shares are trading higher after the company announced it will be acquired by BioMarin.
📈 PositiveBioMarin to acquire rare disease drug developer Amicus for $4.8B
📈 PositiveBioMarin To Acquire Amicus For $14.50/Shr In All-Cash Transaction For Total Equity Value Of ~$4.8B
➖ Neutral'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
📈 PositiveLeerink Partners Downgrades BioMarin Pharmaceutical to Market Perform, Lowers Price Target to $60
📉 NegativeStifel Downgrades BioMarin Pharmaceutical to Hold, Lowers Price Target to $61
📉 NegativeBernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $88
➖ NeutralBioMarin Pharmaceutical Announces FDA Has Accepted Its Supplemental Biologics License Application For PALYNZIQ To Treat Adolescents Aged 12-17 With Phenylketonuria For Priority Review
📈 PositiveFDA Accepts BioMarin's PALYNZIQ Supplemental Biologics License Application For Priority Review To Include Adolescents Aged 12-17 With Phenylketonuria
📈 PositiveTruist Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80
➖ NeutralWells Fargo Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $70
➖ NeutralStifel Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $73
➖ NeutralBarclays Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $80
➖ NeutralHC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $55
➖ NeutralMorgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $98
➖ NeutralBioMarin Pharmaceutical Lowers FY2025 Adj EPS Guidance from $4.40-$4.55 to $3.50-$3.60 vs $3.25 Est; Raises FY2025 Sales Guidance from $3.125B-$3.200B to $3.150B-$3.200B vs $3.171B Est
➖ NeutralBiomarin Pharmaceutical Q3 Adj. EPS $0.12 Misses $0.37 Estimate, Sales $776.133M Miss $780.629M Estimate
📉 NegativeJP Morgan Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $119
📈 PositiveFrequently Asked Questions about BMRN
What is BMRN's current stock price?
What is the analyst price target for BMRN?
What sector is BioMarin Pharmaceutical Inc. in?
What is BMRN's market cap?
Does BMRN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BMRN for comparison